In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-China. Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread. The World Health Organization (WHO) described the most recent coronavirus epidemic as a global pandemic in March 2020. The virus spread triggered a health crisis (the COVID-19 disease) within three months, with socioeconomic implications. No approved targeted-therapies are available for COVID-19, yet. However, it is foreseen that antibody-based treatments may provide an immediate cure for patients. Current neutralizing antibody development studies primarily target the S protein among the structural elements of SARS-CoV-2, which mediates the cell entry of the virus through the angiotensin converting enzyme 2 (ACE2) receptor of host cells. This review aims to provide some of the neutralizing antibody development strategies for SARS-CoV-2 and in vitro and in vivo neutralization assays.
SARS-CoV-2, COVID-19, neutralizing antibodies, human monoclonal antibody, display technologies, human scFv, neutralizing assays, animal models
BALCIOĞLU, BERTAN KORAY; ÖNCÜ, MELİS DENİZCİ; ÖZTÜRK, HASAN ÜMİT; YÜCEL, FATIMA; KAYA, FİLİZ; SERHATLI, MÜGE; POLAT, HİVDA ÜLBEĞİ; TEKİN, ŞABAN; and BAHADIR, AYLİN ÖZDEMİR
"SARS-CoV-2 neutralizing antibody development strategies,"
Turkish Journal of Biology: Vol. 44:
7, Article 9.
Available at: https://journals.tubitak.gov.tr/biology/vol44/iss7/9